阿托伐他汀钙片对冠心病患者心功能及血清hs-CRP、NT-BNP水平的影响

Effect of atorvastatin calcium tablets on cardiac function and serum Hs-CRP,NT-BNP levels in patients with coronary heart disease

目的:分析阿托伐他汀钙片治疗冠心病对患者心功能及血清高敏C反应蛋白(hs-CRP)、氨基末端脑钠肽(NT-BNP)水平的影响。方法:抽取焦作市人民医院2018年3月至2019年5月收治冠心病患者70例,采用随机数字法将其分为对照组与治疗组,每组35例。对照组患者口服曲美他嗪,治疗组患者口服阿托伐他汀钙片。比较两组患者血清hs-CRP、NT-BNP、心功能及不良心脏事件。结果:治疗前两组患者血清hs-CRP、NT-BNP水平比较,差异未见统计学意义(P>0.05),治疗后降低;治疗组患者血清hs-CRP(91.57±12.29)ng/L、NT-BNP(3.41±1.09)pg/L水平低于对照组(P<0.05)。治疗前两组患者6 min步行距离比较,差异未见统计学意义(P>0.05),治疗后增加;治疗组患者6 min步行距离(471.51±20.68)m大于对照组(P<0.05)。治疗前两组患者心功能比较,差异未见统计学意义(P>0.05),治疗后改善;治疗组患者左心室射血分数(LVEF)为(56.63±1.24)%,小于对照组(P>0.05),LVEDD为(69.72±3.31)mm,高于对照组(P>0.05)。治疗组患者心脏不良事件发生率(4/35)低于对照组(P<0.05)。结论:阿托伐他汀钙片在降低冠心病患者血清hs-CRP、NT-BNP水平,保护心功能上有价值,推荐使用。

Objective To investigate the effect of atorvastatin calcium tablets on serum high-sensitivity C reactive protein(hs-CRP),N-terminal brain natriuretic peptide(NT-BNP)levels and cardiac function of coronary heart disease patients.Methods A total of 70 patients with coronary heart disease in Jiaozuo People’s Hospital from March 2018 to May 2019 were enrolled,and were randomly divided into control group and treatment group by random number table methods,with 35 cases in each group.The patients in control group were treated with trimetazidine,while those in treatment group were treated with atorvastatin.Serum hs-CRP,NT-BNP,cardiac function and adverse cardiac reactions were compared between the two groups.Results There was no significant difference in the levels of hs-CRP and NT-BNP between the two groups before treatment(P>0.05),and the levels decreased after treatment;among them,the serum hs-CRP[(91.57±12.29)ng/L]and NT-BNP[(3.41±1.09)pg/L]levels in treatment group were lower than those in control group(P<0.05).There was no statistically significant difference in the 6 min walking distance between the two groups before treatment(P>0.05),which increased after treatment;the 6 min walking distance(471.51±20.68)min the treatment group was greater than that in the control group(P<0.05).There was no statistically significant difference in cardiac function between the two groups before treatment(P>0.05),which was improved after treatment.LVEF[(56.63±1.24)%]in the treatment group was less than that in the control group(P>0.05),and LVEDD[(69.72±3.31)mm]was higher than that in the control group(P>0.05).The incidence of adverse cardiac events in the treatment group(4/35)was lower than that in the control group(P<0.05).Conclusions Atorvastatin calcium tablets can effectively reduce the serum hs-CRP and NT-BNP levels,and protect the cardiac function,which is worthy of recommendation.